Skip to content
OpenCapital
Get started

Citius Pharmaceuticals CTXR Q4 2025 Annual earnings

Reported February 13, 2026 · After market close

Revenue$3.9MMiss by $14.1MDiluted EPS-$0.38Miss by $0.81
Revenue estimate$18.0M
EPS estimate$0.43

Next report

Aug 11, 2026 (in a month)
Revenue estimate$5.5M
EPS estimate-$0.36

Versus estimates

Revenue

Q1 2026$1.7MMiss by $8.6M
Q4 2025$3.9MMiss by $14.1M
Q3 2025$3.9M

Diluted EPS

Q1 2026-$0.95Miss by $0.67
Q4 2025-$0.38Miss by $0.81
Q3 2025-$0.44Miss by $0.20Q2 2025-$0.80Miss by $0.56Q1 2025-$1.27Miss by $0.19Q4 2024-$1.30Miss by $0.05

Ask the moment Citius Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Citius Pharmaceuticals report Q4 2025 earnings?
Citius Pharmaceuticals (CTXR) reported Q4 2025 earnings on February 13, 2026 after market close.
What were Citius Pharmaceuticals's Q4 2025 revenue and EPS?
Citius Pharmaceuticals reported revenue of $3.9M and diluted EPS of $-0.38 for Q4 2025.
Did Citius Pharmaceuticals beat estimates in Q4 2025?
Revenue missed the consensus estimate of $18.0M by $14.1M. EPS missed the consensus estimate of $0.43 by $0.81.
How did Citius Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 70.8% from $-1.30.
Where can I find Citius Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001213900-26-015895) and the 10-K/A periodic report (0001213900-26-008861) directly on SEC EDGAR. The filing index links above go to sec.gov.